Powerful Efficacy. Ensured Safety. Convenient Dosing. Other benefits vs. Glimepiride Long-term powerful efficacy of Empagliflozin vs. Glimepiride¹ zoom Empagliflozin demonstrates lower risk of hypoglycaemia1 FDC: Fixed-dose combination. HbAlc: Glycated haemoglobin. SE: Standard error. EMPA: Empagliflozin. LINA: Linagliptin. Cl: Confidence interval. References:Salsali A, et al. Diabetes Obes Metab. 2018; 20(12):2768-2777.Gallwitz 8, et al. Lancet. 2012;380:475-83. Long-term powerful efficacy of Linagliptin vs. Glimepiride¹ zoom Why Glyxambi®? Why Glyxambi®? Guidelines Efficacy Pleiotropic benefits Cardiovascular safety Renal safety Other safety Differentiation v/s other FDCs Efficacy vs. Glimepiride Other benefits vs. Glimepiride